ACTR-29. A SERIES OF PATIENTS (PTS) WITH RECURRENT GBM (rGBM) TREATED WITH ABT-414 BEVACIZUMAB (BEV) AND CCNU

摘要

ABT-414 showed encouraging results in the phase 2 Intellance 2 rGBM study, but not in the phase 3 Intellance 1 trial, in newly diagnosed EGFR-amplified GBM. We describe a series of pts with rGBM treated with ABT-414 in combination with Bev and CCNU.